Recap: MaxCyte Q3 Earnings
Portfolio Pulse from Benzinga Insights
MaxCyte (NASDAQ:MXCT) reported Q3 earnings, missing estimated earnings by 10.0% with an EPS of $-0.11 versus an estimate of $-0.1. Revenue was down $2.64 million from the same period last year. Last quarter, the company also missed on EPS which was followed by a 10.44% drop in the share price the next day.
November 08, 2023 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
MaxCyte's Q3 earnings missed estimates, with a lower EPS and revenue compared to last year. This follows a trend from last quarter, where a missed EPS led to a 10.44% drop in share price.
MaxCyte's Q3 earnings report shows a miss on both EPS and revenue, which is a negative signal to investors. Given that the last earnings miss was followed by a significant drop in share price, it's reasonable to expect a similar reaction this time.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100